论文部分内容阅读
目的:探讨胰岛素样生长因子ⅡmRNA结合蛋白3(IMP3)在子宫内膜浆液性腺癌中的表达及临床意义。方法:应用免疫组化法检测IMP3在40例子宫内膜浆液性腺癌、10例子宫内膜腺体异型增生、20例子宫内膜单纯性增生、20例正常子宫内膜组织中的阳性表达率,分析其与病变类型的关系,并分析IMP3在子宫内膜浆液性腺癌组中的表达率与临床病理特征的联系。结果:IMP3在子宫内膜浆液性腺癌和子宫内膜腺体异型增生中的阳性表达率分别为72.5%和70.0%,明显高于正常子宫内膜的10%和子宫内膜单纯性增生的15%(均P<0.05)。子宫内膜浆液性腺癌IMP3阳性表达率与患者临床病理分期、淋巴结转移情况相关(P<0.05),而与年龄无关(P>0.05)。结论:IMP3与子宫内膜浆液性腺癌的发生发展及浸润转移有关,可作为一种新的子宫内膜浆液性腺癌早期诊断和治疗的分子标志物,具有重要的临床意义。
Objective: To investigate the expression of insulin-like growth factor Ⅱ-binding protein 3 (IMP3) in endometrial serous adenocarcinoma and its clinical significance. Methods: Immunohistochemical staining was used to detect the expression of IMP3 in 40 cases of endometrial serous adenocarcinoma, 10 cases of endometrial dysplasia, 20 cases of endometrial hyperplasia and 20 cases of normal endometrium The relationship between the expression of IMP3 and the clinicopathological characteristics of endometrial serous adenocarcinoma was analyzed. Results: The positive rates of IMP3 expression in endometrial serous adenocarcinoma and endometrial dysplasia were 72.5% and 70.0%, respectively, which were significantly higher than those in normal endometrium 10% and endometrial hyperplasia 15 % (All P <0.05). The positive expression rate of IMP3 in endometrial serous adenocarcinoma was correlated with the clinicopathological stage and lymph node metastasis (P <0.05), but not with the age (P> 0.05). Conclusion: IMP3 is associated with the development, invasion and metastasis of endometrial serous adenocarcinoma and may be used as a new molecular marker for early diagnosis and treatment of endometrial serous adenocarcinoma. It has important clinical significance.